Patients with obstructive airway diseases (OAD), like
chronic obstructive pulmonary disease (
COPD) and
asthma, may be at increased risk of
pertussis infection.
Pertussis may also trigger
COPD and
asthma exacerbations. Vaccination against
pertussis could help protect OAD patients from the additional burden of
pertussis, but there may be hesitancy related to
vaccine safety and immunogenicity in such patients. We performed a meta-analysis on 5 clinical trials in adults receiving reduced-
antigen tetanus-
diphtheria-acellular
pertussis vaccine (Tdap,
Boostrix, GSK), from which we selected participants on active OAD treatment. We compared immunogenicity and reactogenicity outcomes of the meta-analysis with data from the overall populations of Tdap-vaccinated adults from 6 Tdap trials (including the 5 in the meta-analysis). The meta-analysis comprised 222 adults on active standard OAD treatment. One month post-Tdap, 89.0% and 97.2% of these adults, respectively, achieved seroprotective anti-
diphtheria and anti-
tetanus antibody concentrations; 78.3%-96.1% showed booster responses across the 3
pertussis antigens. These rates were consistent with those in the comparator population. The most frequently reported solicited local and systemic adverse events within 4 days post-Tdap were injection site
pain (47.7%) and
fatigue (19.3%), with low rates of grade 3 intensity (0.9% and 2.8%). This was consistent with Tdap reactogenicity in the comparator population. Evaluation of unsolicited and serious adverse events within 1 month post-Tdap did not identify safety concerns. In conclusion, Tdap was immunogenic and well tolerated in adults under active standard OAD treatment, with immunogenicity and safety profiles consistent with those in a comparator population representing the general adult population.